Helen Usansky

694 total citations
16 papers, 389 citations indexed

About

Helen Usansky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Helen Usansky has authored 16 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Helen Usansky's work include Drug Transport and Resistance Mechanisms (4 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Melanoma and MAPK Pathways (3 papers). Helen Usansky is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Melanoma and MAPK Pathways (3 papers). Helen Usansky collaborates with scholars based in United States, Netherlands and Canada. Helen Usansky's co-authors include Patrick J. Sinko, Brahm Goldstein, Thomas L. Deckwerth, Christopher F. Toombs, Michael A. Insko, Csaba Szabó, Edward A. Wintner, Khurram Jamil, Michael Cooreman and Peidi Hu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Heart Journal.

In The Last Decade

Helen Usansky

14 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Helen Usansky United States 9 84 82 77 63 58 16 389
Graham Scott United Kingdom 13 274 3.3× 33 0.4× 45 0.6× 171 2.7× 71 1.2× 25 606
Shinji Kobuchi Japan 13 52 0.6× 198 2.4× 6 0.1× 6 0.1× 122 2.1× 61 529
W. E. Bachmann Germany 15 10 0.1× 51 0.6× 30 0.4× 17 0.3× 137 2.4× 78 707
Taiji Sawamoto Japan 17 19 0.2× 159 1.9× 6 0.1× 10 0.2× 100 1.7× 30 644
Aihua Bao China 14 8 0.1× 44 0.5× 22 0.3× 13 0.2× 186 3.2× 30 538
Brian Kevin Park United Kingdom 12 52 0.6× 38 0.5× 21 0.3× 20 0.3× 63 1.1× 12 378
Alan Chuan‐Ying Lai Taiwan 14 35 0.4× 114 1.4× 5 0.1× 27 0.4× 295 5.1× 18 713
David A. Sandham United Kingdom 14 7 0.1× 18 0.2× 18 0.2× 23 0.4× 132 2.3× 29 453
Tsutomu Arai Japan 16 22 0.3× 170 2.1× 7 0.1× 6 0.1× 145 2.5× 35 575
C. Kimura Japan 11 76 0.9× 23 0.3× 14 0.2× 54 0.9× 145 2.5× 33 487

Countries citing papers authored by Helen Usansky

Since Specialization
Citations

This map shows the geographic impact of Helen Usansky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Usansky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Usansky more than expected).

Fields of papers citing papers by Helen Usansky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Usansky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Usansky. The network helps show where Helen Usansky may publish in the future.

Co-authorship network of co-authors of Helen Usansky

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Usansky. A scholar is included among the top collaborators of Helen Usansky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Usansky. Helen Usansky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Stein, Daniel S., et al.. (2024). The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration. British Journal of Clinical Pharmacology. 91(4). 1191–1197. 2 indexed citations
3.
4.
Smith, Roger A., David J. Zammit, Nitin K. Damle, et al.. (2021). ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Molecular Cancer Therapeutics. 20(8). 1327–1337. 19 indexed citations
5.
6.
Reddy, Sanjeeva, et al.. (2020). Abstract B05: ASN007, an oral ERK1/2 inhibitor, shows strong antitumor activity across a panel of KRAS subtype mutant cancer models. Molecular Cancer Research. 18(5_Supplement). B05–B05. 2 indexed citations
7.
8.
Tolcher, Anthony W., Ryan J. Sullivan, Drew Rasco, et al.. (2019). Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors. Molecular Cancer Therapeutics. 18(12_Supplement). PR09–PR09. 3 indexed citations
9.
Rasco, Drew, Nehal J. Lakhani, Ryan P. Sullivan, et al.. (2018). Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors. Cancer Research. 78(13_Supplement). CT019–CT019. 1 indexed citations
10.
Barta, Stefan K., Drew Rasco, Andy I. Chen, et al.. (2018). Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS7084–TPS7084. 1 indexed citations
11.
Dellinger, R.P., Stephen Trzeciak, Gerard J. Criner, et al.. (2012). Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome. Critical Care. 16(2). R36–R36. 23 indexed citations
12.
Toombs, Christopher F., Michael A. Insko, Edward A. Wintner, et al.. (2010). Detection of exhaled hydrogen sulphide gas in healthy human volunteers during intravenous administration of sodium sulphide. British Journal of Clinical Pharmacology. 69(6). 626–636. 106 indexed citations
13.
Usansky, Helen, Peidi Hu, & Patrick J. Sinko. (2008). Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats. Drug Metabolism and Disposition. 36(5). 863–869. 28 indexed citations
14.
Usansky, Helen & Patrick J. Sinko. (2005). Estimating Human Drug Oral Absorption Kinetics from Caco-2 Permeability Using an Absorption-Disposition Model: Model Development and Evaluation and Derivation of Analytical Solutions for ka and Fa. Journal of Pharmacology and Experimental Therapeutics. 314(1). 391–399. 52 indexed citations
15.
Sinko, Patrick J., Jeevan Kunta, Helen Usansky, & Barbara Perry. (2004). Differentiation of Gut and Hepatic First Pass Metabolism and Secretion of Saquinavir in Ported Rabbits. Journal of Pharmacology and Experimental Therapeutics. 310(1). 359–366. 25 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Graham Scott Breakdown of academic impact, for papers by Shinji Kobuchi Breakdown of academic impact, for papers by W. E. Bachmann Breakdown of academic impact, for papers by Taiji Sawamoto Breakdown of academic impact, for papers by Aihua Bao Breakdown of academic impact, for papers by Brian Kevin Park Breakdown of academic impact, for papers by Alan Chuan‐Ying Lai Breakdown of academic impact, for papers by David A. Sandham Breakdown of academic impact, for papers by Tsutomu Arai Breakdown of academic impact, for papers by C. Kimura
Rankless by CCL
2026